Portal de investigação
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Tocchetti, CG
- Ameri, P
- de Boer, RA
- D'Alessandra, Y
- Russo, M
- Sorriento, D
- Ciccarelli, M
- Kiss, B
- Bertrand, L
- Dawson, D
- Giacca, M
- Hamdani, N
- Linke, WA
- Mayr, M
- van der Velden, J
- Zacchigna, S
- Ghigo, A
- Hirsch, E
- Lyon, AR
- Görbe, A
- Ferdinandy, P
- Madonna, R
- Heymans, S
- Thum, T
Unidades de investigação
Abstract
In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.
Dados da publicação
- ISSN/ISSNe:
- 1755-3245, 0008-6363
- Tipo:
- Article
- Páginas:
- 1820-1834
- DOI:
- 10.1093/cvr/cvaa222
- Link para outro recurso:
- www.scopus.com
Cardiovascular Research Oxford University Press
Citações Recebidas na Web of Science: 39
Citações Recebidas na Scopus: 60
Documentos
- Não há documentos
Filiações
Keywords
- Cardio-Oncology; Common pathways in heart failure and cancer; Multicellular and multiorgan mechanisms
Financiamento
Proyectos asociados
Cardiac Remodelling and “Recovery” in Pregnancy as a Model to Understand the Mechanisms of CV Diseases.
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Observacional Académico (PERIMYR) . SP Cardiologia . 2019
Remodelling adversely impacts arrhythmic outcome following isolated aortic valve replacement surgery
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Clínico Académico (Remodelling) . 2020
The Heart under Pressure: Mechanisms underlying HEpEF Secondary to chronic pressure Overload or Metabolic Syndrome
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Clínico Académico . 2020
Citar a publicação
Tocchetti CG,Ameri P,de Boer RA,D'Alessandra Y,Russo M,Sorriento D,Ciccarelli M,Kiss B,Bertrand L,Dawson D,Falcao I,Giacca M,Hamdani N,Linke WA,Mayr M,van der Velden J,Zacchigna S,Ghigo A,Hirsch E,Lyon AR,Görbe A,Ferdinandy P,Madonna R,Heymans S,Thum T. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc. Res. 2020. 116. (11):p. 1820-1834. IF:10,787. (1).
